מדינה: אוסטרליה
שפה: אנגלית
מקור: Department of Health (Therapeutic Goods Administration)
oseltamivir phosphate, Quantity: 98.5 mg (Equivalent: oseltamivir, Qty mg)
Accelagen Pty Ltd
Capsule, hard
Excipient Ingredients: iron oxide red; croscarmellose sodium; purified talc; iron oxide black; Gelatin; titanium dioxide; pregelatinised maize starch; iron oxide yellow; sodium stearylfumarate; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; potassium hydroxide
Oral
10 capsules
(S4) Prescription Only Medicine
TALMINEX is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,TALMINEX is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus.
Visual Identification: Size 2 hard gelatin capsules with grey opaque body with black band, imprinted with M and light yellow opaque cap imprinted with 75 mg; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2020-02-25
TALMINEX Consumer Medicine Information Talminex CMI Ver 2.0 1 TALMINEX CAPSULES Oseltamivir phosphate CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Talminex capsules. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Talminex against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT TALMINEX IS USED FOR Talminex is an antiviral medicine containing the active ingredient oseltamivir. Talminex is used for the treatment and prevention of influenza (an infection caused by the influenza virus). It has no effect on the common cold or other respiratory virus infections. Talminex belongs to a group of medicines called neuraminidase inhibitors. These medicines attack the influenza virus and prevent it from spreading inside your body. Talminex is absorbed to the key sites of influenza infection and treats the cause. Taking Talminex means you feel better faster. You will also be less likely to develop complications of influenza, such as bronchitis, pneumonia and sinusitis. Typical symptoms of influenza include fever, headache, muscle aches, sore throat, cough and generally feeling unwell. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY TALMINEX HAS BEEN PRESCRIBED FOR YOU. Talminex is not addictive. This medicine is available only with a doctor's prescription. ASK YOUR DOCTOR ABOUT HAVING THE INFLUENZA VACCINATION. Vaccination every year is the best way to prevent influenza. TALMINEX Consumer Medicine Information Talminex CMI Ver 2.0 2 BEFORE YOU TAKE TALMINEX When you must not take it DO NOT TALMINEX IF: 1. YOU HAVE HAD AN ALLERGIC REACTION TO OSELTAMIVIR OR ANY INGREDIENTS LISTED AT THE END OF THIS LEAFLET Some of the symptoms of an allergic reaction may incl קרא את המסמך השלם
Talminex PI Ver 3.0 1 AUSTRALIAN PRODUCT INFORMATION – TALMINEX (OSELTAMIVIR PHOSPHATE) 1. NAME OF THE MEDICINE Oseltamivir phosphate 2. QUALITIATIVE AND QUANTITATIVE COMPOSITION TALMINEX is available as hard gelatin capsules for oral use. Each 75 mg hard capsule of TALMINEX contains 98.5 mg oseltamivir phosphate, equivalent to 75 mg of oseltamivir. Each 45 mg hard capsule of TALMINEX contains 59.1 mg oseltamivir phosphate, equivalent to 45 mg of oseltamivir. Each 30 mg hard capsule of TALMINEX contains 39.4 mg of oseltamivir phosphate, equivalent to 30 mg of oseltamivir. Gelatin capsules contain sulphites. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3. PHARMACEUTICAL FORM Hard capsule. 30 mg: Size “4” hard gelatin capsules with light yellow opaque colour body with black colour band, imprinted with “M” and light yellow opaque colour cap imprinted with “30 mg” 45 mg: Size “4” hard gelatin capsules with grey opaque colour body with black colour band, imprinted with “M” and grey opaque colour cap imprinted with “45 mg”. 75 mg: Size “2” hard gelatin capsules with grey opaque colour body with black colour band, imprinted with “M” and light yellow opaque colour cap imprinted with “75 mg”. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TALMINEX is indicated for the treatment of infections due to influenza A and B viruses in adults and children including full-term neonates. Treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection. TALMINEX is indicated for the prevention of influenza in adults and children aged 1 year and older. Vaccination is the preferred method of routine prophylaxis against infection with influenza virus. 4.2 DOSE AND METHOD OF ADMINISTRATION TALMINEX may be taken with or without food (see Section 5.2 PHARMACOKINETIC PROPERTIES). However, taking with food may enhance tolerability in some patients. TREATMENT OF INFLUENZA Treatment should begin within the first or se קרא את המסמך השלם